Editas Medicine, based in Cambridge, MA, is a pioneering biotechnology company dedicated to harnessing the power of CRISPR gene editing technology to develop transformative and durable genomic medicines for individuals worldwide living with serious diseases. Their mission is to discover, develop, manufacture, and commercialize a robust pipeline of medicines aimed at repairing broken genes and improving patient outcomes.
With a focus on delivering innovative solutions, Editas Medicine is committed to developing a broad range of experimental medicines using CRISPR technology to revise, remove, and replace DNA in a highly targeted manner. Their goal is to serve the global community by providing transformative treatments to a wide range of patients in need.
Generated from the website